200 related articles for article (PubMed ID: 37465991)
1. Longitudinal efficacy and safety modeling and simulation framework to aid dose selection of belantamab mafodotin for patients with multiple myeloma.
Collins J; van Noort M; Rathi C; Post TM; Struemper H; Jewell RC; Ferron-Brady G
CPT Pharmacometrics Syst Pharmacol; 2023 Oct; 12(10):1411-1424. PubMed ID: 37465991
[TBL] [Abstract][Full Text] [Related]
2. Exposure-Response Analyses for Therapeutic Dose Selection of Belantamab Mafodotin in Patients With Relapsed/Refractory Multiple Myeloma.
Ferron-Brady G; Rathi C; Collins J; Struemper H; Opalinska J; Visser S; Jewell RC
Clin Pharmacol Ther; 2021 Nov; 110(5):1282-1292. PubMed ID: 34468979
[TBL] [Abstract][Full Text] [Related]
3. EMA Review of Belantamab Mafodotin (Blenrep) for the Treatment of Adult Patients with Relapsed/Refractory Multiple Myeloma.
Tzogani K; Penttilä K; Lähteenvuo J; Lapveteläinen T; Lopez Anglada L; Prieto C; Garcia-Ochoa B; Enzmann H; Gisselbrecht C; Delgado J; Pignatti F
Oncologist; 2021 Jan; 26(1):70-76. PubMed ID: 33179377
[TBL] [Abstract][Full Text] [Related]
4. Belantamab mafodotin for relapsed or refractory multiple myeloma (DREAMM-2): a two-arm, randomised, open-label, phase 2 study.
Lonial S; Lee HC; Badros A; Trudel S; Nooka AK; Chari A; Abdallah AO; Callander N; Lendvai N; Sborov D; Suvannasankha A; Weisel K; Karlin L; Libby E; Arnulf B; Facon T; Hulin C; Kortüm KM; Rodríguez-Otero P; Usmani SZ; Hari P; Baz R; Quach H; Moreau P; Voorhees PM; Gupta I; Hoos A; Zhi E; Baron J; Piontek T; Lewis E; Jewell RC; Dettman EJ; Popat R; Esposti SD; Opalinska J; Richardson P; Cohen AD
Lancet Oncol; 2020 Feb; 21(2):207-221. PubMed ID: 31859245
[TBL] [Abstract][Full Text] [Related]
5. Safety, pharmacokinetics, and efficacy of belantamab mafodotin monotherapy in Japanese patients with relapsed or refractory multiple myeloma: DREAMM-11.
Iida S; Sunami K; Mishima Y; Fujii T; Kato H; Terao T; Matsuzawa Y; Matsubara M; Crossman T; Kremer BE; Gupta I
Int J Hematol; 2023 Nov; 118(5):596-608. PubMed ID: 37668832
[TBL] [Abstract][Full Text] [Related]
6. Population pharmacokinetics of belantamab mafodotin, a BCMA-targeting agent in patients with relapsed/refractory multiple myeloma.
Rathi C; Collins J; Struemper H; Opalinska J; Jewell RC; Ferron-Brady G
CPT Pharmacometrics Syst Pharmacol; 2021 Aug; 10(8):851-863. PubMed ID: 34076364
[TBL] [Abstract][Full Text] [Related]
7. Belantamab mafodotin for the treatment of multiple myeloma.
Wang B; Wu C; Zhong Q; Ling L; Wu Z; Yu B; Gao X; Zeng H; Yang DH
Drugs Today (Barc); 2021 Nov; 57(11):653-663. PubMed ID: 34821879
[TBL] [Abstract][Full Text] [Related]
8. Corneal Epithelial Findings in Patients with Multiple Myeloma Treated with Antibody-Drug Conjugate Belantamab Mafodotin in the Pivotal, Randomized, DREAMM-2 Study.
Farooq AV; Degli Esposti S; Popat R; Thulasi P; Lonial S; Nooka AK; Jakubowiak A; Sborov D; Zaugg BE; Badros AZ; Jeng BH; Callander NS; Opalinska J; Baron J; Piontek T; Byrne J; Gupta I; Colby K
Ophthalmol Ther; 2020 Dec; 9(4):889-911. PubMed ID: 32712806
[TBL] [Abstract][Full Text] [Related]
9. Belantamab Mafodotin for the Treatment of Multiple Myeloma: An Overview of the Clinical Efficacy and Safety.
Offidani M; Corvatta L; Morè S; Olivieri A
Drug Des Devel Ther; 2021; 15():2401-2415. PubMed ID: 34103900
[TBL] [Abstract][Full Text] [Related]
10. FDA Approval Summary: Belantamab Mafodotin for Patients with Relapsed or Refractory Multiple Myeloma.
Baines AC; Ershler R; Kanapuru B; Xu Q; Shen G; Li L; Ma L; Okusanya OO; Simpson NE; Nguyen W; Theoret MR; Pazdur R; Gormley NJ
Clin Cancer Res; 2022 Nov; 28(21):4629-4633. PubMed ID: 35736811
[TBL] [Abstract][Full Text] [Related]
11. Belantamab Mafodotin: First Approval.
Markham A
Drugs; 2020 Oct; 80(15):1607-1613. PubMed ID: 32936437
[TBL] [Abstract][Full Text] [Related]
12. Single-agent belantamab mafodotin in patients with relapsed/refractory multiple myeloma: Final analysis of the DREAMM-2 trial.
Nooka AK; Cohen AD; Lee HC; Badros A; Suvannasankha A; Callander N; Abdallah AO; Trudel S; Chari A; Libby EN; Chaudhry M; Hultcrantz M; Kortüm KM; Popat R; Sborov D; Hakim S; Lewis E; Gorsh B; Bhushan B; McKeown A; Gupta I; Opalinska J; Richardson PG; Lonial S
Cancer; 2023 Dec; 129(23):3746-3760. PubMed ID: 37622738
[TBL] [Abstract][Full Text] [Related]
13. Belantamab mafodotin, pomalidomide and dexamethasone in refractory multiple myeloma: a phase 1/2 trial.
Trudel S; McCurdy A; Louzada ML; Parkin S; White D; Chu MP; Kotb R; Mian H; Othman I; Su J; Khan A; Gul E; Reece D
Nat Med; 2024 Feb; 30(2):543-551. PubMed ID: 38177852
[TBL] [Abstract][Full Text] [Related]
14. Ocular Toxicity of Belantamab Mafodotin, an Oncological Perspective of Management in Relapsed and Refractory Multiple Myeloma.
Wahab A; Rafae A; Mushtaq K; Masood A; Ehsan H; Khakwani M; Khan A
Front Oncol; 2021; 11():678634. PubMed ID: 34046363
[TBL] [Abstract][Full Text] [Related]
15. Belantamab mafodotin for relapsed or refractory multiple myeloma.
Gil-Sierra MD; Briceño-Casado MDP
J Oncol Pharm Pract; 2022 Sep; 28(6):1375-1380. PubMed ID: 35306910
[No Abstract] [Full Text] [Related]
16. Belantamab mafodotin in the treatment of relapsed or refractory multiple myeloma.
Sheikh S; Lebel E; Trudel S
Future Oncol; 2020 Dec; 16(34):2783-2798. PubMed ID: 32875817
[TBL] [Abstract][Full Text] [Related]
17. Longer term outcomes with single-agent belantamab mafodotin in patients with relapsed or refractory multiple myeloma: 13-month follow-up from the pivotal DREAMM-2 study.
Lonial S; Lee HC; Badros A; Trudel S; Nooka AK; Chari A; Abdallah AO; Callander N; Sborov D; Suvannasankha A; Weisel K; Voorhees PM; Womersley L; Baron J; Piontek T; Lewis E; Opalinska J; Gupta I; Cohen AD
Cancer; 2021 Nov; 127(22):4198-4212. PubMed ID: 34314018
[TBL] [Abstract][Full Text] [Related]
18. Belantamab Mafodotin and Relapsed/Refractory Multiple Myeloma: This Is Not Game Over.
Condorelli A; Garibaldi B; Gagliano C; Romano A; Del Fabro V; Parrinello NL; Longo A; Cosentino S; Di Raimondo F; Conticello C
Acta Haematol; 2021 Nov; ():. PubMed ID: 34839282
[TBL] [Abstract][Full Text] [Related]
19. Single-agent belantamab mafodotin for relapsed/refractory multiple myeloma: analysis of the lyophilised presentation cohort from the pivotal DREAMM-2 study.
Richardson PG; Lee HC; Abdallah AO; Cohen AD; Kapoor P; Voorhees PM; Hoos A; Wang K; Baron J; Piontek T; Byrne J; Richmond S; Jewell RC; Opalinska J; Gupta I; Lonial S
Blood Cancer J; 2020 Oct; 10(10):106. PubMed ID: 33097687
[TBL] [Abstract][Full Text] [Related]
20. Management of belantamab mafodotin-associated corneal events in patients with relapsed or refractory multiple myeloma (RRMM).
Lonial S; Nooka AK; Thulasi P; Badros AZ; Jeng BH; Callander NS; Potter HA; Sborov D; Zaugg BE; Popat R; Degli Esposti S; Byrne J; Opalinska J; Baron J; Piontek T; Gupta I; Dana R; Farooq AV; Colby K; Jakubowiak A
Blood Cancer J; 2021 May; 11(5):103. PubMed ID: 34039952
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
